FOLLOWUS
Research and development of the effective components of panaxdiol saponin as new chinese patent medicine for treating hemocytopenia
- Chinese Journal of Integrative Medicine Vol. 18, Issue 12, Pages: 897-902(2012)
- Affiliations：
1. Institution of Hematology Research, The First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China
2. Department of Hematology, St George Hospital and St George Clinical School, University of New South Wales, Kogarah,Australia
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 30271597), Australia-China Institutional Links Research Program by International Development Program of Education Australia (No. IDP 2-8), Science and Technology Foundation of Zhjiang Province, China (No. 2004C23002), and Natural Science Foundation of Zhjiang Province, China (No. ZD0007)
DOI：10.1007/s11655-012-1292-4
CLC：Published：2012，
Published Online：13 December 2012，
Scan for full text
Gao, Rl., Chong, B.H. Research and development of the effective components of panaxdiol saponin as new chinese patent medicine for treating hemocytopenia., Chin. J. Integr. Med. 18, 897–902 (2012). https://doi.org/10.1007/s11655-012-1292-4
Rui-lan Gao, Beng Hock Chong. Research and development of the effective components of panaxdiol saponin as new chinese patent medicine for treating hemocytopenia. [J]. Chinese Journal of Integrative Medicine 18(12):897-902(2012)
Gao, Rl., Chong, B.H. Research and development of the effective components of panaxdiol saponin as new chinese patent medicine for treating hemocytopenia., Chin. J. Integr. Med. 18, 897–902 (2012). https://doi.org/10.1007/s11655-012-1292-4 DOI：
Rui-lan Gao, Beng Hock Chong. Research and development of the effective components of panaxdiol saponin as new chinese patent medicine for treating hemocytopenia. [J]. Chinese Journal of Integrative Medicine 18(12):897-902(2012) DOI： 10.1007/s11655-012-1292-4.
摘要
Pancytopenia (hemocytopenia) such as pr imary immune primary thrombocytopenia (ITP)
aplastic anemia and chronic neutropenia (agnogenic leukocytopenia) were of ten t reated by glucocor t icoids
androgen and often treated glucocorticoids
immunosuppressive agents at present
but the response to these treatments has not been always satisfactory
and may cause serious adverse events. Our research has identified a biological active component in ginseng extract and the active component
panaxadiol saponins component (PDS-C)
was isolated from total saponins of ginsenosides
and formulated into capsules named as Painengda (派能达). We successfully obtained approval from State Food and Drug Administration (SFDA) of China in 2010 to conduct clinical trials of PDS-C as class-five new Chinese patent medicine. Phase I and phase II clinical trials of PDS-C and Painengda Capsule were carried out in the treatment of ITP and agnogenic leukocytopenia. The composition and content of PDS-C have been analyzed and defined by high-performance liquid chromatography-chromatographymass spectrometry (HPLC-MS) and HPLC using specific monomers of ginsenosides as the reference standards. mass PDS-C is very efficacious for treating mice and rats with ITP and aplastic anemia
and myelosuppression caused by chemotherapy or radiation. Our animal model studies and cell biology and molecular biology experiments demonstrated that PDS-C possessed dual activities
namely that of promoting proliferation and differentiation of hematopoietic progenitor cells
and that of regulating the immune function. PDS-C and Painengda Capsule as a new Chinese patent medicine have been successfully transferred to industry. We believe that PDS-C is effective and safe in the treatment of refractory hemocytopenia. The advantages are that it is effective in small doses
it is convenient to use because of its oral administration
its lack of adverse events
it could be used alone or in combination with pharmacological agents
which improve the efficacy and decrease adverse events.
Abstract
Pancytopenia (hemocytopenia) such as pr imary immune primary thrombocytopenia (ITP)
aplastic anemia and chronic neutropenia (agnogenic leukocytopenia) were of ten t reated by glucocor t icoids
androgen and often treated glucocorticoids
immunosuppressive agents at present
but the response to these treatments has not been always satisfactory
and may cause serious adverse events. Our research has identified a biological active component in ginseng extract and the active component
panaxadiol saponins component (PDS-C)
was isolated from total saponins of ginsenosides
and formulated into capsules named as Painengda (派能达). We successfully obtained approval from State Food and Drug Administration (SFDA) of China in 2010 to conduct clinical trials of PDS-C as class-five new Chinese patent medicine. Phase I and phase II clinical trials of PDS-C and Painengda Capsule were carried out in the treatment of ITP and agnogenic leukocytopenia. The composition and content of PDS-C have been analyzed and defined by high-performance liquid chromatography-chromatographymass spectrometry (HPLC-MS) and HPLC using specific monomers of ginsenosides as the reference standards. mass PDS-C is very efficacious for treating mice and rats with ITP and aplastic anemia
and myelosuppression caused by chemotherapy or radiation. Our animal model studies and cell biology and molecular biology experiments demonstrated that PDS-C possessed dual activities
namely that of promoting proliferation and differentiation of hematopoietic progenitor cells
and that of regulating the immune function. PDS-C and Painengda Capsule as a new Chinese patent medicine have been successfully transferred to industry. We believe that PDS-C is effective and safe in the treatment of refractory hemocytopenia. The advantages are that it is effective in small doses
it is convenient to use because of its oral administration
its lack of adverse events
it could be used alone or in combination with pharmacological agents
which improve the efficacy and decrease adverse events.
关键词
panaxadiol saponinsPainengdapreclinical trialhemocytopeniaprimary immune thrombocytopeniaagnogenic leukocytopenia
Keywords
panaxadiol saponinsPainengdapreclinical trialhemocytopeniaprimary immune thrombocytopeniaagnogenic leukocytopenia
references
Gao RL, Xu CL, Jin JM. Effect of total saponins of Panax ginseng on hematopoietic progenitor cells in normal human and aplastic anemia patients. Chin J Integr Tradit West Med (Chin) 1992;12:261–262, 285–287.
Gao RL, Jin JM, Chong BH. The study of total saponins of panax ginseng in human hematopoiesis. J Zhejiang Coll of Tradit Chin Med (Chin) 1998;22:37–38.
Chen XH, Gao RL, Xu WH. Effect of ginsenosides in inducing proliferation and transcription factor of erythrocytic, granulo-monocytic and megakarocytic cell lines. Chin J Integr Tradit West Med (Chin) 2001;21:40–42.
Jin J, Tao H, Gao R. Effect of ginsenosides on proliferation and differentiation of human CD34+ hematopoietic stem/progenitor cells. Chin J Integr Tradit West Med (Chin) 2000;20:673–676.
Gao R, Wu C, Chong BH. The intracellular signaling pathway initiated by ginsenosides in hematopoietic cells. Natl Med J Chin (Chin) 1999;20:292–295.
Gao RL, Wu CQ, Tao H, Chong BH. Ginsenosides stimulate proliferation of human megakaryocytic progenitors by up-regulation of GATA-binding activity. Thrombosis Haemostasis 1999;Suppl:818.
Gao RL, Jin JM, Wu CQ, Chong BH. Ginsenosides stimulate proliferation of human megakaryocytic progenitors though by GATA transcription factor. J Clin Hematol (Chin) 1999;12:50–54.
Gao RL, Niu YP, Chong BH. Experimental observation of function of total saponin of ginseng to leukemia ancestral cells. Shanghai J Tradit Chin Med (Chin) 1999;9:46–47.
Gao RL, Wu CQ, Chong BH. Ginsenosides induce phosphorylation of GATA-2 transcription factors in megakaryocyte. J Zhejiang Clin Med (Chin) 1999;1:7–9.
Fang GL, Gao RL, Jin JM. Effect of ginseng total saponin on proliferation of mouse hematopoietic progenitor cells. J Zhejiang Med (Chin) 2000;27:408–409.
Gao RL, Xu WH, Chen XH, Chong BH. Up-regulation binding activity of GATA and AP-1 transcription factors initiated by panaxadiol of ginseng in hematopoietic cells. Cell Bio Inter 2001;25:1052–1053.
Gao RL. Research and development new Chinese materia medica for treatment of refractory hematopathy by establishment and application multiple technique platforms. Chin J Integr Med 2007;13:95–97.
Qian XD, Ma FS, Gao RL. Efficacy observation of Sheng-xue-ling Capsules (total saponins of panax ginseng) in treating chronic aplastic anemia. J Zhejiang Clin Med (Chin) 2004;6:952–953.
Shen YP, Zhou YH, Yu RX. Clinical observation of total saponins of Panax ginseng in combination with cyclosporin A for treatment of chronic aplastic anemia. J Zhejiang Med (Chin) 2001;23:178–179.
Ma FS, Gao RL, Lin XJ, Xu JL, Miao Q, Chen XH, et al. Clinical research of Shengxueling Capsule (total ginsenosides) for treatment of immune thrombocytopenia. J Zhejiang Chin Med Univ (Chin) 2012;36:137–140
Shao KD, Zhou YH, Shen YP, Ye BD, Gao RL, Zhang Y. Treatment of 37 patients with refractory idiopathic thrombocytopenic purpura by Shengxueling. Chin J Integr Med 2007;13:33–36.
Zhou YH, Yu RX, Luo XS. Clinical observation of total saponins of Panax ginseng in treating neutrophil granulocytopenia. Chin J Integr Tradit West Med (Chin) 2000;20:539–540.
Gao RL, Ma FS, Wu CQ, Xu JL, Chong BH. Panax ginsenosides for treating refractory blood diseases as well as up-regulation and transcription of genes in relationship with hematopoiesis. Bull Med Res (Chin) 2002;31:23–24.
Gai Y, Gao RL, Niu YP. Effect of Panax notoginsenosides on the proliferation of hematopoietic progenitor cells in mice with immune-mediated aplastic anemia. Chin J Integr Tradit West Med (Chin) 2003;23:680–683
Fang GL, Gao RL, Lin XJ, Jin JM. Effects of Ginseng panaxadiol saponin on proliferation and differentiation of human bone marrow CD34+ cells. J Exp Hematol (Chin) 2007;15:776–779.
0
Views
91
Downloads
15
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
